AMICUS THERAPEUTICS, INC. 8-K

What Happened Amicus Therapeutics, Inc. announced that the Ministry of Economics and Finance in France granted foreign direct investment (FDI) clearance for its previously disclosed merger with BioMarin Pharmaceutical Inc. The Merger Agreement was signed December 19, 2025 (Merger Sub: Lynx Merger Sub 1, Inc.), and with the French FDI Clearance received on April 23, 2026, the companies state the remaining conditions to closing are those that must be satisfied at closing. The Merger is expected to close on April 27, 2026, at which point Amicus would become a wholly owned subsidiary of BioMarin.

Key Details

• Merger Agreement date: December 19, 2025 (BioMarin and Lynx Merger Sub 1, Inc. with Amicus).
• French FDI Clearance granted: April 23, 2026, by the Ministry of Economics and Finance (France).
• Expected closing date: April 27, 2026, subject to closing-time conditions.
• Post-closing structure: Amicus to survive the merger as a wholly owned subsidiary of BioMarin.

Why It Matters For investors, the French FDI Clearance removed a key regulatory hurdle and brings the transaction to the final pre-closing stage, making the planned acquisition likely to complete imminently (subject to any last-minute closing conditions). The filing also includes customary forward-looking statement language and points investors to the companies’ SEC filings (including their 2025 Form 10-Ks and Amicus’ Proxy Statement) for risks that could affect timing or completion.